{"id":"standard-of-care-iv-antihypertensive","safety":{"commonSideEffects":[{"rate":"null","effect":"Cough"},{"rate":"null","effect":"Dizziness"},{"rate":"null","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL3121562","moleculeType":"Small molecule","molecularWeight":"784.98"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This is achieved through the inhibition of the angiotensin II type 1 receptor, which is a key component of the renin-angiotensin-aldosterone system. By blocking this receptor, the drug reduces the vasoconstrictive and aldosterone-secreting effects of angiotensin II, resulting in decreased blood pressure and reduced strain on the heart.","oneSentence":"Blocks the action of angiotensin II at its receptor, leading to vasodilation and decreased blood pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:36:22.741Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"}]},"trialDetails":[{"nctId":"NCT04893733","phase":"PHASE4","title":"Intravenous Administration of Vitamin B Complex Improves Renal Recovery in Patients With AKI","status":"COMPLETED","sponsor":"Caja Nacional de Salud","startDate":"2020-09-01","conditions":"Acute Kidney Injury","enrollment":260},{"nctId":"NCT04592380","phase":"PHASE3","title":"Clevidipine vs Placebo or Standard of Care for Dyspnea and Blood Pressure Control in AHF","status":"WITHDRAWN","sponsor":"The Medicines Company","startDate":"2014-08","conditions":"Dyspnea, Hypertension, Acute Heart Failure","enrollment":""},{"nctId":"NCT03640221","phase":"PHASE4","title":"Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes.","status":"WITHDRAWN","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-01","conditions":"Hypertension, Diabetes Mellitus, Type 2","enrollment":""},{"nctId":"NCT00803634","phase":"PHASE3","title":"Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO)","status":"COMPLETED","sponsor":"The Medicines Company","startDate":"2008-12","conditions":"Hypertension, Heart Failure","enrollment":117}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["nitroglycerin","nicardipine","sodium nitroprusside","isosorbide dinitrate","hydralizine"],"phase":"phase_3","status":"active","brandName":"Standard of Care IV antihypertensive","genericName":"Standard of Care IV antihypertensive","companyName":"The Medicines Company","companyId":"the-medicines-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Blocks the action of angiotensin II at its receptor, leading to vasodilation and decreased blood pressure. Used for Hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}